Valuation: Polaris Group

Market Cap 9.29B 292M 252M 236M 215M 404M 27.88B 410M 2.77B 1.08B 13.97B 1.09B 1.07B 46.47B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.8B 308M 266M 249M 227M 427M 29.43B 433M 2.92B 1.15B 14.75B 1.16B 1.13B 49.05B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.37%
1 week-2.70%
Current month-0.46%
1 month-15.62%
3 months-36.09%
6 months-63.88%
Current year-65.27%
1 week 10.8
Extreme 10.8
11.25
1 month 10.8
Extreme 10.8
12.65
Current year 10.8
Extreme 10.8
35.95
1 year 10.8
Extreme 10.8
44.55
3 years 10.8
Extreme 10.8
88.1
5 years 10.8
Extreme 10.8
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.37%-2.70%-69.45%-86.86% 294M
+0.68%-2.28%+1.91%+19.70% 48.42B
+4.68%+3.88%+489.85%+634.04% 43.66B
+4.36%+0.90%+13.44%+88.39% 39.51B
+2.14%-0.26%+25.36%+12.68% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.02%-2.95% - - 16.32B
+2.27%-1.63%+28.01%+133.68% 16.15B
-0.62%-0.06%+3.95%+27.74% 14.16B
+1.99%+2.59%+81.02%+42.18% 13.37B
Average +1.40%-0.49%+66.08%+103.30% 26.34B
Weighted average by Cap. +2.07%-0.63%+102.15%+152.19%

Financials

2024 2025
Net sales 107M 3.36M 2.9M 2.72M 2.48M 4.66M 321M 4.73M 31.9M 12.5M 161M 12.61M 12.34M 535M 40.6M 1.27M 1.1M 1.03M 941K 1.77M 122M 1.79M 12.1M 4.74M 61.07M 4.79M 4.68M 203M
Net income -2.5B -78.59M -67.84M -63.65M -57.97M -109M -7.51B -111M -746M -292M -3.76B -295M -289M -12.52B -3.93B -123M -106M -99.88M -90.97M -171M -11.79B -173M -1.17B -459M -5.91B -463M -453M -19.65B
Net Debt 9.19M 289K 249K 234K 213K 400K 27.6M 406K 2.74M 1.07M 13.83M 1.08M 1.06M 45.99M 517M 16.23M 14.01M 13.15M 11.97M 22.51M 1.55B 22.83M 154M 60.39M 777M 60.94M 59.62M 2.59B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
17/08/26 TWD 10.80 -1.37% 813,283
14/08/26 TWD 10.95 -1.35% 435,515
13/08/26 TWD 11.10 +1.37% 932,924
12/08/26 TWD 10.95 -0.45% 634,528
11/08/26 TWD 11.00 -2.22% 811,642
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock